<DOC>
	<DOCNO>NCT02475629</DOCNO>
	<brief_summary>This Phase 3 , single arm , multicenter study evaluate safety effectiveness ibalizumab treatment-experienced patient infect multi-drug resistant HIV-1 .</brief_summary>
	<brief_title>Ibalizumab Plus Optimized Background Regimen Patient With Multi-Drug Resistant HIV</brief_title>
	<detailed_description>This Phase 3 , single arm , multicenter study evaluate safety effectiveness ibalizumab treatment-experienced patient infect multi-drug resistant HIV-1 . Patients must treat HAART least 6 month fail recently fail ( i.e. , last 8 week ) therapy determine baseline viral load . Days 0-6 study `` control period . '' During Days 0 6 patient monitor current failing therapy ( therapy , patient fail discontinue treatment within 8 week precede Screening ) . Days 7-13 study `` essential monotherapy period . '' During Days 7 13 patient continue current failing therapy receive one 2000 mg dose ( load dose ) ibalizumab Day 7 . Day 7 Baseline treatment period ( Day 7-Week 25 ) . Day 14-Week 25 study `` maintenance period . '' On Day 14 ( primary endpoint ) , OBR initiate must include least one agent patient 's virus susceptible . Beginning Day 21 , 800 mg ibalizumab administer every 2 week Week 23 . End Study evaluation perform Week 25 , follow-up visit conduct Week 29 .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Are capable understand voluntarily sign inform consent document Have document HIV1 infection official , sign , write history ( e.g. , laboratory report ) , otherwise HIVantibody test perform Have acquire immunodeficiency syndrome ( AIDS ) define event 3 month Screening , cutaneous Kaposi 's sarcoma wasting syndrome due HIV Are able willing comply protocol requirement procedure Have life expectancy &gt; 6 month . Have viral load &gt; 1,000 copies/mL document resistance least one antiretroviral medication three class antiretroviral medication measure resistance test Have history least 6 month antiretroviral treatment Are receive stable highly active antiretroviral regimen least 8 week Screening willing continue regimen Day 14 , OR ( past 8 week ) fail therapy willing stay therapy Day 14 Have full viral sensitivity/susceptibility least one antiretroviral agent , ibalizumab , determine screen resistance test willing able treat least one agent patient 's viral isolate fully sensitive/susceptible accord screen resistance test component OBR If sexually active , willing use effective method contraception study 30 day last administration study drug Any active AIDSdefining illness per Category C condition accord Centers Disease Control Prevention ( CDC ) Classification System HIV Infection , follow exception : cutaneous Kaposi 's sarcoma wasting syndrome due HIV Any significant disease ( HIV1 infection ) clinically significant finding , include psychiatric behavioral problem , determine screening , medical history and/or physical examination , investigator 's opinion , would preclude patient participate study Any significant acute illness within 1 week initial administration study drug Any active infection secondary HIV require acute therapy ; however , patient require maintenance therapy ( i.e. , secondary prophylaxis opportunistic infection ) eligible study . Any immunomodulating therapy ( include interferon ) , systemic steroid , systemic chemotherapy within 12 week Enrollment Any prior exposure ibalizumab ( formerly TNX355 Hu5A8 ) Any vaccination within 7 day Enrollment Any female patient either pregnant , intend become pregnant , currently breastfeed Any current alcohol illicit drug use , investigator 's opinion , interfere patient 's ability comply study schedule protocol evaluation Any previous clinically significant allergy hypersensitivity excipient ibalizumab formulation Any radiation therapy 28 day first administration investigational medication Any Grade 3 4 laboratory abnormality accord Division AIDS grade scale , except follow asymptomatic Grade 3 event triglyceride elevation total cholesterol elevation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>